A purple cactus pear (Opuntia ficus-indica) extract (CP) was encapsulated in double emulsions (DE) gelled with gelatin (DE-CP-G) and with gelatin and transglutaminase (DE-CP-GT), as well as in a DE with a liquid external aqueous phase (DE-CP), in order to study the retention of betanin as colorant agent. Both gelled DEs showed a predominantly elastic behavior, in contrast with DE-CP. The degradation rate constant of betanin was significantly higher in DE-CP-GT (90.2 x 10-3 days-1) than in DE-CP-G (11.0 x 10-3 days-1) and DE-CP (14.6 x 10-3 days-1) during cold-storage (4 °C). A shift towards yellow color was found in all the systems during cold-storage (4 °C) and after thermal treatment (70°C/30 min), especially in DE-CP-GT, denoting a higher degradation of betanin. Betalamic acid, cyclo-Dopa 5-O-β-glucoside, 17-decarboxy-betanin and neobetanin were identified by UHPLC-MS/MS as degradation products of betanin.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964817 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0227866 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Recovery trajectories after major abdominal surgery: A retrospective pooled cohort study.
Acta Anaesthesiol Scand
February 2025
Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia.
Background: Recovery from major surgery can be difficult to predict given the many factors involved in treating disease and restoring preoperative function. Postoperative recovery metrics such as length of stay, complications, and mortality are typically described. However, large data quantities for patient-reported recovery are scarce.
View Article and Find Full Text PDFUnravelling Eribulin's role in metastatic breast cancer: evaluating benefits for both triple negative and non-triple negative patients in real-world scenarios in resource-constrained settings.
Ecancermedicalscience
November 2024
Department of Palliative Medicine, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi 221005, India.
Background: Metastatic breast cancer (MBC) patients have numerous options for treatment. However, it is essential to consider treatments with favorable toxicity profiles and convenient modes of administration. Eribulin has shown effectiveness in aggressive MBC, but there is a lack of sufficient real-world data specific to Indian patients.
View Article and Find Full Text PDFAddition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer.
Signal Transduct Target Ther
December 2024
Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, PR China.
This phase 2/3 trial (NCT04856787) assessed the efficacy and safety of SHR-1701, a bifunctional protein targeting PD-L1 and TGF-β, in combination with BP102 (a bevacizumab biosimilar) and XELOX (capecitabine plus oxaliplatin) as a first-line treatment for unresectable metastatic colorectal cancer (mCRC). In this phase 2 study, a total of 62 patients with untreated, histologically confirmed colorectal adenocarcinoma and no prior systemic therapy for metastatic disease were enrolled. Patients received SHR-1701 (30 mg/kg), bevacizumab (7.
View Article and Find Full Text PDFRisks of major arterial and venous thrombotic diseases after hospitalisation for influenza, pneumonia, and COVID-19: A population-wide cohort in 2.6 million people in Wales.
Thromb Res
January 2025
British Heart Foundation Data Science Centre, Health Data Research UK, London, UK; Centre for Clinical Brain Sciences, University of Edinburgh, UK.
Article Synopsis
- Pneumonia, influenza, and COVID-19 can increase the risk of blood clots due to inflammation affecting the thrombotic system, but long-term risks post-hospitalization remain unclear.
- The study analyzed health data from adults in Wales to assess the incidence of arterial and venous thrombosis after hospitalizations due to COVID-19 and compared it with rates after pneumonia or influenza hospitalizations.
- Results indicated heightened risk for arterial thrombosis shortly after COVID-19 hospitalization, with adjusted hazard ratios showing a significant decrease in risk over time, but still elevated compared to individuals without COVID-19 hospitalizations.
Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses.
BJC Rep
June 2024
Department of Pathology, Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Article Synopsis
- - The study investigated the effectiveness of ixabepilone (IXA) combined with bevacizumab (BEV) in treating ovarian cancers resistant to paclitaxel, revealing that the combination therapy significantly improves overall response rates (ORR) and progression-free survival (PFS) compared to ixabepilone alone.
- - A phase 2 clinical trial randomly assigned 76 patients, showing that those receiving IXA + BEV had a much higher ORR (38.4% vs. 8.1%) and greater PFS (5.5 months vs. 2.2 months) and overall survival (OS) (10.3 months vs. 6.0 months) despite many participants requiring
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!